64262-23-3

Usage

Uses

Used in Pharmaceutical Synthesis:
1-n-Propylpiperazine dihydrobromide is used as a key intermediate in the synthesis of amidines and sulfonamides of 5and 6-amino-2,3-bis(4-alkyl-1-piperazazinyl)quinoxalines. These compounds have potential applications in the development of new drugs and therapeutic agents, particularly in the treatment of various diseases and medical conditions.
In the synthesis process, 1-n-Propylpiperazine dihydrobromide reacts with other chemical compounds to form the desired amidines and sulfonamides. This reaction is crucial for the creation of new pharmaceutical agents with improved properties, such as enhanced efficacy, selectivity, and reduced side effects.
Overall, 1-n-Propylpiperazine dihydrobromide plays a significant role in the development of novel pharmaceuticals and chemical compounds, contributing to advancements in medicine and healthcare. Its versatility and reactivity make it an essential component in the synthesis of various organic compounds with potential applications in different industries.

InChI:InChI=1S/C7H16N2.2BrH/c1-2-5-9-6-3-8-4-7-9;;/h8H,2-7H2,1H3;2*1H

Upstream product

• 71172-70-8 4-propyl-piperazine-1-carboxylic acid ethyl ester 

Downstream Products

• 150208-58-5 1-<(3,4-dichlorophenyl)acetyl>-4-(1-propyl)piperazine 
• 4489-50-3 2-(4-propyl-piperazin-1-yl)-ethylamine 
• 208754-40-9 4-((4-propylpiperazin-1-yl)methyl)benzoic acid 
• 1295584-90-5 N-(2-benzoyl-4-chlorophenyl)-2-(4-propyl-1-piperazinyl)-2-phenylacetamide 
• 1416401-49-4 C₂₀H₃₀N₄S 

Relevant academic research and scientific papers

Novel water-soluble sedative-hypnotic agents: Isoindolin-1-one derivatives

We developed new intravenous sedative-hypnotic compounds with the isoindolin-1-one skeleton focusing on the water-soluble property and in vivo safety. We synthesized approximately 170 derivatives and evaluated their hypnotic effects by intravenous administration of the compounds to mice. A series of the 2-phenyl-3-[2-(4-methyl-1-piperazinyl)-2-oxoethyl]isoindolin-1-one analogs, 3(-), 5(-), 27(-), and 47(-) [JM-1232(-)], showed potent sedative-hypnotic activity with good water solubility and a wide safety margin. The hypnotic doses (HD50s) of these 4 compounds when administered to mice were 2.35, 1.90, 2.17, and 3.12 mg/kg, respectively, and the lethal doses (LD50s) were 88.67, 64.69, >120, and >120 mg/kg, respectively. The therapeutic indexes (LD50/HD50) were 37.73, 34.05, >55.30, and >38.46, respectively. Among these compound, 47(-) [JM-1232(-)] is being considered as the most potential candidate for clinical trials in humans.

Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction

Compounds of the formulae (IA) and (IB): wherein R1is C1to C3alkyl optionally substituted with phenyl, Het or a N-linked heterocyclic group selected from piperidinyl and morpholinyl; wherein said phenyl group is optionally substituted by one or more substitutents selected from C1to C4alkoxy; halo; CN; CF3; OCF3or C1to C4alkyl wherein said C1to C4alkyl group is optionally substituted by C1to C4haloalkyl or haloalkoxy either of which is substituted by one or more halo atoms; R2is C1to C6alkyl and R13is OR3or NR5R6, or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of, inter alia, male erectile dysfunction (MED) and female sexual dysfunction (FSD).